Torasemide

Torasemide is a high-ceiling loop diuretic of the pyridine-sulfonylurea class. It inhibits the Na+/K+/2Cl- luminal carrier in the thick ascending limb of Henle's loop, producing potent natriuresis and diuresis. Unlike furosemide, torasemide features high, predictable oral bioavailability (around 80%), a longer duration of action, and antialdosterone properties that decrease myocardial collagen accumulation. Indicated for edema associated with congestive heart failure, chronic renal failure, and hepatic cirrhosis, and for essential hypertension.

Torasemide and Spironolactone is a balanced dual-action diuretic formulation. Torasemide is a high-potency pyridine-sulfonylurea loop diuretic that inhibits the Na+/K+/2Cl- cotransporter in the thick ascending limb of the loop of Henle, while spironolactone is a competitive aldosterone receptor antagonist in the distal convoluted tubule and collecting duct. Spironolactone prevents loop diuretic-induced potassium wasting and secondary hyperaldosteronism, reducing cardiac fibrosis while promoting sustained natriuresis. Indicated for resistant edema associated with congestive heart failure, hepatic cirrhosis with ascites, and nephrotic syndrome.

Torasemide (10mg) and Spironolactone (25mg) Tablets is a fixed-dose loop and potassium-sparing diuretic combination on the WHO Model List framework. Torasemide inhibits the Na+/K+/2Cl- symporter in the thick ascending limb of Henle's loop, producing potent natriuresis and diuresis. Spironolactone competitively antagonizes the mineralocorticoid aldosterone receptor in the distal convoluted tubule and collecting duct, promoting sodium and water excretion while conserving potassium and magnesium ions. Indicated for refractory edema and ascites associated with congestive heart failure, hepatic cirrhosis, and nephrotic syndrome.

Torasemide (10mg) and Amiloride (5mg) Tablets is a fixed-dose loop and potassium-sparing diuretic combination. Torasemide blocks the Na+/K+/2Cl- cotransporter in the loop of Henle, while amiloride selectively blocks epithelial sodium channels (ENaC) in the late distal tubule and cortical collecting duct, preventing potassium loss driven by torasemide's high distal tubular sodium delivery. Indicated for refractory edema associated with congestive heart failure, nephrotic syndrome, and hepatic cirrhosis.